Indeed, the disruption of the menin–MLL1 interaction with small molecule inhibitors leads to pronounced anti-leukemic effects in pre-clinical models of leukemia with MLL1-r and NPM1-mut (11, 12, 14, 16, 17, 18). The gene discussed is KMT2A; the disease is leukemia.